As a specialty research organization, our mission is to push research forward by supporting the early stage advancements that can be afforded to all patients
As life science and healthcare companies look to drive inclusivity into clinical trials, we are enhancing these approaches, with the help of StarSense, to ensure comprehensive and robust advancements are realized to reach all patients.
We're enhancing the approach to reducing risks and amendments by applying evidence based appraoches in your clinical trial design.
Patient Recruitment & Engagement
Augmenting the ability of looking to underlying factors that may inhibit your strategy to reach a diverse patient plan.
Phase I-II Clinical Trials
Rubix LS can help you track the impact of new drugs and establish proof of concept faster to ove from early concept development to full trial management.
Decentralized & Hybrid Trial Launch
Rubix LS augmented Decentralized/Hybrid trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are.
Therapeutic Area Specialties
A host of new and re-emerging pathogens are quickly emerging from climate and environmental impact across the globe. The study of infectious disease and vaccines is as complex as the populations and environments they impact.
Our unique specialization is to launch programs, no matter what environment, that are tailored solutions at every stage of development.
At Rubix LS, we have specialized research teams of professionals that provide unique and inclusively customized solutions for organizations working to advance broader public health goals.
Ultra Rate Disease
Small. Hard-to-find. Unmet patient needs.
These are the mission pillars that has helped build our focus to be specialists in inclusive patient research and support that broadens the term to all patient populations with rare diseases that are in need of rare disease care to bring new treatments to them and their families.
It is estimated that there are approximately 7000 rare diseases identified while only 5% have therapeies. As an emerging global public health priority, we’re working towards designing evidence-based analytics that serves the advancement of innovation for the disparate population.